Pregnancy outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: a Japanese experience and updated review

International Journal of Hematology

Volumn 103, Issue 6, 2016, Pages 703-712

  Miyasaka, Naoyuki ^a,m   Miura, Osamu ^a,m   Kawaguchi, Tatsuya ^b,m   Arima, Nobuyoshi ^c,m   Morishita, Eriko ^d,m   Usuki, Kensuke ^e,m   Morita, Yasuyoshi ^f,m   Nishiwaki, Kaichi ^g,m   Ninomiya, Haruhiko ^h,m   Gotoh, Akihiko ^i,m   Imashuku, Shinsaku ^j,m   Urabe, Akio ^e,m   Shichishima, Tsutomu ^k,m   Nishimura, Jun ichi ^l,m   Kanakura, Yuzuru ^l,m  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

^c Kitano Hospital   (Japan)

^d KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^e Nippon Telegraph and Telephone Corporation Medical Center Tokyo   (Japan)

^f KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h UNIVERSITY OF TSUKUBA   (Japan)

ⁱ TOKYO MEDICAL UNIVERSITY   (Japan)

^j Takasago seibu Hospital   (Japan)

^k FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^l OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^m Working Group for Pregnancy in PNH   (Japan)

more..

Author keywords

Eculizumab; Paroxysmal nocturnal hemoglobinuria; Pregnancy

Indexed keywords

CYCLOSPORIN; D DIMER; DANAPAROID; ECULIZUMAB; FOLIC ACID; HEMOGLOBIN; HEPARIN; IMMUNOSUPPRESSIVE AGENT; IRON; LACTATE DEHYDROGENASE; LOW MOLECULAR WEIGHT HEPARIN; MENINGOCOCCUS VACCINE; MONOCLONAL ANTIBODY;

ADULT; APLASTIC ANEMIA; ARTICLE; BODY WEIGHT; BREAKTHROUGH HEMOLYSIS; BREAST FEEDING; BREAST MILK; CASE REPORT; CESAREAN SECTION; COMMON COLD; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG MILK LEVEL; DRUG WITHDRAWAL; EMERGENCY SURGERY; ERYTHROCYTE TRANSFUSION; FEMALE; GESTATIONAL AGE; GIRL; HEMOGLOBIN BLOOD LEVEL; HEMOLYSIS; HOSPITAL DISCHARGE; HUMAN; IMMATURITY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INTRAVASCULAR HEMOLYSIS; JAPANESE (PEOPLE); LABORATORY TEST; MATERNAL DEATH; MENINGOCOCCOSIS; NEWBORN DEATH; NEWBORN INTENSIVE CARE; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PREECLAMPSIA; PREGNANCY OUTCOME; PREGNANT WOMAN; PREMATURE LABOR; PROPHYLAXIS; PROTEINURIA; PUERPERIUM; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; UMBILICAL CORD BLOOD; VACCINATION; VAGINAL DELIVERY; VITAMIN SUPPLEMENTATION; HEMOGLOBINURIA, PAROXYSMAL; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HEMOGLOBINURIA, PAROXYSMAL; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PREGNANCY OUTCOME;

EID: 84957624267     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-016-1946-x     Document Type: Article

References (32)

1. Miyata T, Takeda J, Iida Y, Yamada N, Inoue N, Takahashi M, et al. The cloning of PIG-A, a component in the early step of GPI-anchor biosynthesis. Science. 1993;259(5099):1318–20.
2. Miyata T, Yamada N, Iida Y, Nishimura J, Takeda J, Kitani T, et al. Abnormalities of PIG-A transcripts in granulocytes from patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1994;330(4):249–55.
3. Takeda J, Miyata T, Kawagoe K, Iida Y, Endo Y, Fujita T, et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell. 1993;73(4):703–11.
4. Parker C, Omine M, Richards S, Nishimura J, Bessler M, Ware R, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood. 2005;106(12):3699–709.
5. Brodsky RA. How I treat paroxysmal nocturnal hemoglobinuria. Blood. 2009;113(26):6522–7.
6. Luzzatto L, Gianfaldoni G, Notaro R. Management of paroxysmal nocturnal haemoglobinuria: a personal view. Br J Haematol. 2011;153(6):709–20.
7. Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995;333(19):1253–8.
8. Socie G, Mary JY, de Gramont A, Rio B, Leporrier M, Rose C, et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology. Lancet. 1996;348(9027):573–7.
9. Nishimura J, Kanakura Y, Ware RE, Shichishima T, Nakakuma H, Ninomiya H, et al. Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine. 2004;83(3):193–207.
10. de Latour RP, Mary JY, Salanoubat C, Terriou L, Etienne G, Mohty M, et al. Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories. Blood. 2008;112(8):3099–106.
11. Fieni S, Bonfanti L, Gramellini D, Benassi L, Delsignore R. Clinical management of paroxysmal nocturnal hemoglobinuria in pregnancy: a case report and updated review. Obstet Gynecol Surv. 2006;61(9):593–601.
12. Hillmen P, Young NS, Schubert J, Brodsky RA, Socie G, Muus P, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355(12):1233–43.
13. Kanakura Y, Ohyashiki K, Shichishima T, Okamoto S, Ando K, Ninomiya H, et al. Long-term efficacy and safety of eculizumab in Japanese patients with PNH: AEGIS trial. Int J Hematol. 2013;98(4):406–16.
14. Ando Y, Kida M, Saika M, Chizuka A, Hangaishi A, Urabe A, et al. Pregnancy and delivery in a PNH patient treated with eculizumab. Rinsho Ketsueki Jpn J Clin Hematol. 2014;55(11):2288–93.
15. Danilov AV, Smith H, Craigo S, Feeney DM, Relias V, Miller KB. Paroxysmal nocturnal hemoglobinuria (PNH) and pregnancy in the era of eculizumab. Leuk Res. 2009;33(6):e4–5.
16. Marasca R, Coluccio V, Santachiara R, Leonardi G, Torelli G, Notaro R, et al. Pregnancy in PNH: another eculizumab baby. Br J Haematol. 2010;150(6):707–8.
17. Sharma R, Keyzner A, Liu J, Bradley T, Allen SL. Successful pregnancy outcome in paroxysmal nocturnal hemoglobinuria (PNH) following escalated eculizumab dosing to control breakthrough hemolysis. Leuk Res Rep. 2015;4(1):36–8.
18. Patriquin C, Leber B. Increased eculizumab requirements during pregnancy in a patient with paroxysmal nocturnal hemoglobinuria: case report and review of the literature. Clin Case Rep. 2015;3(2):88–91.
19. Kelly R, Arnold L, Richards S, Hill A, Bomken C, Hanley J, et al. The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab. Br J Haematol. 2010;149(3):446–50.
20. de Guibert S, de Latour RP, Varoqueaux N, Labussiere H, Rio B, Jaulmes D, et al. Paroxysmal nocturnal hemoglobinuria and pregnancy before the eculizumab era: the French experience. Haematologica. 2011;96(9):1276–83.
21. Tedder RS, Nelson M, Eisen V. Effects on serum complement of normal and pre-eclamptic pregnancy and of oral contraceptives. Br J Exp Pathol. 1975;56(5):389–95.
22. Franchini M. Haemostasis and pregnancy. Thromb Haemost. 2006;95(3):401–13.
23. Danilov AV, Brodsky RA, Craigo S, Smith H, Miller KB. Managing a pregnant patient with paroxysmal nocturnal hemoglobinuria in the era of eculizumab. Leuk Res. 2010;34(5):566–71.
24. de Jesus GR, Rodrigues G, de Jesus NR, Levy RA. Pregnancy morbidity in antiphospholipid syndrome: what is the impact of treatment? Curr Rheumatol Rep. 2014;16(2):403.
25. Kappler S, Ronan-Bentle S, Graham A. Thrombotic microangiopathies (TTP, HUS, HELLP). Emerg Med Clin North Am. 2014;32(3):649–71.
26. Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA. 2005;293(13):1653–62.
27. Thomas TC, Rollins SA, Rother RP, Giannoni MA, Hartman SL, Elliott EA, et al. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol. 1996;33(17–18):1389–401.
28. Brodsky RA, Young NS, Antonioli E, Risitano AM, Schrezenmeier H, Schubert J, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 2008;111(4):1840–7.
29. Roberts JM, Gammill HS. Preeclampsia: recent insights. Hypertension. 2005;46(6):1243–9.
30. Hashira S, Okitsu-Negishi S, Yoshino K. Placental transfer of IgG subclasses in a Japanese population. Pediatr Int. 2000;42(4):337–42.
31. Hallstensen RF, Bergseth G, Foss S, Jaeger S, Gedde-Dahl T, Holt J, et al. Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn. Immunobiology. 2015;220(4):452–9.
32. Kelly RJ, Hochsmann B, Szer J, Kulasekararaj A, de Guibert S, Roth A, et al. Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2015;373(11):1032–9.